Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Overweight 2Obesity 2Melanoma 2Substance Withdrawal Syndrome 1Skin Neoplasms 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Chronic Pain 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Temozolomide 393Radiotherapy 196Bevacizumab 156Radiation 77Magnetic Resonance Spectroscopy 68Lomustine 47Surgical Procedures, Operative 42Carmustine 41pembrolizumab 39Irinotecan 38Nivolumab 32Specimen Handling 27Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Drug Therapy 21Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13poly ICLC 12atezolizumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glioblastoma × Naltrexone × Clear all
NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed
110 enrolled 9 charts
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡